Search results for " blood coagulation"

showing 7 items of 17 documents

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy

2009

SUMMARY BACKGROUND: More and more people with severe hemophilia reach an old age thanks to an effective treatment. There is no information on the health status and quality of life of elderly people with hemophilia born at a time when replacement therapy was hardly available. METHODS: Italian patients with severe hemophilia, aged >or=65 years and hence born in 1942 or earlier, were compared with elderly men without bleeding disorders matched for age, sex, geography and social status. The following aspects were evaluated: concomitant illness, orthopedic status, physical functioning and cognitive status. Measurements of generic and disease-specific health-related quality of life were also obta…

Malemedicine.medical_specialtyPediatricshamophilia healt status agingActivities of daily livingHealth StatusPopulationActivities of Daily Living; Aged; Blood Coagulation Factors; Hemophilia A; Humans; Italy; Male; Health Status; Quality of LifeHemophilia ASettore MED/15 - Malattie Del SangueQuality of lifehemic and lymphatic diseasesArthropathyActivities of Daily LivingMedicineHumanseducationDepression (differential diagnoses)Agededucation.field_of_studybusiness.industryHematologymedicine.diseaseBlood Coagulation FactorsItalyConcomitantOrthopedic surgeryPhysical therapyQuality of LifebusinessSocial status
researchProduct

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct

Blood Component Therapy and Coagulopathy in Trauma: A Systematic Review of the Literature from the Trauma Update Group

2016

Background Traumatic coagulopathy is thought to increase mortality and its treatment to reduce preventable deaths. However, there is still uncertainty in this field, and available literature results may have been overestimated. Methods We searched the MEDLINE database using the PubMed platform. We formulated four queries investigating the prognostic weight of traumatic coagulopathy defined according to conventional laboratory testing, and the effectiveness in reducing mortality of three different treatments aimed at contrasting coagulopathy (high fresh frozen plasma/packed red blood cells ratios, fibrinogen, and tranexamic acid administration). Randomized controlled trials were selected alo…

Tranexamic acidPhysiologyGlycobiologylcsh:MedicineCardiovascular MedicinePathology and Laboratory MedicineBiochemistryVascular Medicinelaw.inventionDatabase and Informatics MethodsFresh frozen plasma0302 clinical medicineRandomized controlled trialCoagulopathyAnimal CellslawAntifibrinolytic agentFibrinogen; Fresh frozen plasma; Tranexamic acid; Antifibrinolytic agent.Medicine and Health Sciences030212 general & internal medicineDatabase Searchinglcsh:ScienceMultidisciplinaryPlasma ExchangeHematologyBlood Coagulation DisordersClinical Laboratory SciencesAntifibrinolytic AgentsBody FluidsBloodtraumaTranexamic AcidCardiovascular DiseasesResearch DesignMeta-analysisObservational StudiesFresh frozen plasmaAnatomyCellular TypesResearch ArticlePlateletsmedicine.medical_specialtyDeath RatesHemorrhageBlood Component TransfusionResearch and Analysis MethodsExternal validity03 medical and health sciencesSigns and SymptomsPopulation MetricsDiagnostic MedicinemedicineCoagulopathyHumansBlood TransfusionMortalityIntensive care medicineBlood CoagulationAntifibrinolytic Agents; Blood Coagulation Disorders; Humans; Mortality; Plasma Exchange; Tranexamic Acid; Wounds and Injuries; Blood Component Transfusion; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DemographyGlycoproteinsBlood CellsAntifibrinolytic agentPopulation BiologyCoagulation DisordersTransfusion Medicinebusiness.industrylcsh:RBleedingAntifibrinolytic agent.Biology and Life SciencesFibrinogen030208 emergency & critical care medicineCell Biologymedicine.diseaseSurgeryPeople and PlacesWounds and Injurieslcsh:QObservational studyPacked red blood cellsbusinessPLOS ONE
researchProduct

α-Tocopherol Modulates Phosphatidylserine Externalization in Erythrocytes

2006

Objective— The aim of the present study was to assess the effect of α-tocopherol, the main vitamin E isomer on phosphatidylserine (PS) exposure at the surface of circulating erythrocytes, and to determine consequences on erythrocyte properties. Methods and Results— In vitro α-tocopherol enrichment of isolated erythrocytes significantly decreased PS externalization as assessed by lower Annexin V-fluorescein isothiocyanate labeling. Plasma phospholipid transfer protein (PLTP) transfers vitamin E, and both α-and γ-tocopherol accumulated in circulating erythrocytes from PLTP-deficient homozygous (PLTP −/− ) mice as compared with wild-type mice. In agreement with in vitro studies, vitamin E–enr…

Vitaminmedicine.medical_specialtyErythrocytesWhole Blood Coagulation Timemedicine.medical_treatmentalpha-TocopherolPhospholipidCell SeparationPhosphatidylserinesBiologyFibrin Fibrinogen Degradation ProductsMicechemistry.chemical_compoundAnnexinIn vivoPhospholipid transfer proteinInternal medicinemedicineAnimalsTocopherolPhospholipid Transfer ProteinsBlood CoagulationMice KnockoutVitamin EErythrocyte MembraneHomozygotePhosphatidylserinePhenotypeEndocrinologychemistryBiochemistryCardiology and Cardiovascular MedicineOxidation-ReductionBiomarkersArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats.

2013

Substantial improvements in the safety of blood and plasma products for the management of bleeding disorders have been achieved in recent decades. This has led some clinicians to believe that the infectious threat is over and that inhibitor formation is the foremost complication of hemophilia therapy. On the contrary, elimination of all microbes from blood is difficult, potentially impossible, and there are always threats from emerging pathogens. The risk of infection transmission is also increasing due to greater exposure to products, increasing prophylaxis and high-dose regimens for immune tolerance, and longevity of hemophilia patients. Current products can be considered "reasonably safe…

medicine.medical_specialtyLong term treatmentContext (language use)Hemophilia AInfectionsEmerging infectionsSAFERHumans; Blood Coagulation Disorders; Hemophilia A; Blood Transfusion; InfectionmedicineHumansBlood TransfusionIntensive care medicinePathogenTransmission (medicine)business.industryRisk of infectionTransfusion ReactionHematologyBlood Coagulation Disordersmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaThrombosisSurgeryHemostasisPlasma productsBlood safetyCardiology and Cardiovascular MedicinebusinessInfectionSeminars in thrombosis and hemostasis
researchProduct

Benign intracranial hypertension associated to blood coagulation derangements

2006

Abstract Background Benign Intracranial Hypertension (BIH) may be caused, at least in part, by intracranial sinus thrombosis. Thrombosis is normally due to derangements in blood coagulation cascade which may predispose to abnormal clotting activation or deficiency in natural inhibitors' control. The aim of the study is to examine the strength of the association between risk factors for thrombosis and BIH. Patients and methods The incidence of prothrombotic abnormalities among a randomly investigated cohort of 17 patients with BIH, was compared with 51 healthy subjects matched for sex, age, body mass index, height and social background. Results The number of subjects with protein C deficienc…

medicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologysymbols.namesakeProtein C deficiencyIntracranial hypertension blood coagulation fibrinolysisInternal medicineFibrinolysismedicineFisher's exact testAngiologyHematologybiologylcsh:RC633-647.5business.industrylcsh:Diseases of the blood and blood-forming organsHematologymedicine.diseaseThrombosisMethylenetetrahydrofolate reductasesymbolsbiology.proteinOriginal Clinical InvestigationbusinessBody mass index
researchProduct